leadf
logo-loader
viewBetterLife Pharma Inc

BetterLife Pharma seeks patent protection for new 2-Bromo-LSD formulations to treat depression and mood disorders

BetterLife is the only company that can synthesize an LSD molecule (non-psychedelic) that eliminates regulatory barriers to working with a Schedule 1 substance 

BetterLife Pharma Inc - BetterLife Pharma Inc seeks patent protection for new 2-Bromo-LSD (TD-0148A) formulations to treat depression and mood disorders
2-Bromo-LSD is a nontoxic second-generation LSD-derived molecule that mimics the therapeutic potential of LSD, without the psychedelic effects or hallucinations

BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) announced Monday that it has applied for patent protection for its new 2-Bromo-LSD (TD-0148A) formulations to treat depression and mood disorders.

2-Bromo-LSD is a nontoxic second-generation LSD-derived molecule that mimics the therapeutic potential of LSD, without the psychedelic effects or hallucinations. 

BetterLife noted that its recent C$10 million acquisition of the assets of Transcend Biodynamics makes it the only company able to synthesize 2-Bromo-LSD utilizing a patented process which obviates the need to first synthesize LSD-25 — eliminating the regulatory barriers of working with a Schedule 1 substance. 

READ: BetterLife Pharma adds psychedelic industry leaders to its senior management team

“The invention covered by this provisional patent filing holds great promise for the treatment of various psychiatric disorders, and helps us advance on our path to becoming a leader in the psychedelic drug space which is estimated to become a $6.85 billion dollar industry by 2027 alone,” said BetterLife CEO Ahmad Doroudian in a statement. 

“We are excited to be developing and bringing to market treatments addressing a range of mental health conditions, including depression and anxiety.”

BetterLife, based in Vancouver, also is developing drug candidates from a broad set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus (COVID-19) and human papillomavirus, or to directly inhibit tumors to treat specific types of cancer.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: BetterLife Pharma Inc

Price: 1.1435 USD

OTCQB:BETRF
Market: OTCQB
Market Cap: $57.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

BetterLife Pharma reveals clinical trial updates on its treatment for...

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian updates Proactive on the group's clinical trials progress, revealing it has engaged the clinical research organization Pharmaceutical Solutions Ltd to manage its study of AP-003 as a treatment for mild-to-moderate...

on 10/16/2020

2 min read